Opus Genetics Chief Operating Officer Joseph Schachle Sells 4,644 Shares to Satisfy Tax Obligations

Automatic Share Sale Triggered by Restricted Stock Vesting Event

Joseph K. Schachle, serving as Chief Operating Officer of Opus Genetics, Inc., sold 4,644 shares of common stock on July 23, 2026, according to the disclosure filing. The transaction was executed at $2.94 per share and was not a discretionary trade initiated by the executive. Rather, the company's filing explicitly states that the shares were sold automatically on behalf of Schachle as required by Opus Genetics to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award.

This type of transaction is routine in corporate compensation structures where companies manage tax withholding by automatically selling a portion of newly vested equity awards. The predetermined nature of such sales distinguishes them from open-market transactions that reflect an executive's investment decisions. Schachle's sale represents a technical adjustment to his equity holdings rather than a change in his overall commitment to the company.

Schachle's Ongoing Beneficial Ownership Position

Following the July 23 sale, the disclosure shows that Schachle directly beneficially owns 291,440 shares of Opus Genetics common stock. This remaining position was held in direct ownership form, meaning Schachle maintains full control and beneficial interest in these shares without any intermediate holding structures. The magnitude of his post-transaction shareholding indicates that his equity stake in the company remains substantial despite the automatic sale triggered by tax withholding requirements.

The filing provides no information regarding the total number of restricted stock units that vested, the original size of the award, or the value of the tax withholding obligation that necessitated the automatic share sale. Investors seeking additional details about Schachle's equity compensation structure and the extent of his restricted stock holdings would need to consult other company disclosures, such as proxy statements or annual reports that provide comprehensive executive compensation tables.

Executive Leadership and Tax Compliance at Opus Genetics

The automatic share sale underscores standard corporate practices for managing executive compensation tax obligations. Public company executives frequently receive equity awards that are subject to various vesting schedules and tax events. When restricted stock units settle, tax liability is triggered for the executive based on the fair market value of the shares at vesting. Companies typically offer or require automatic share sales to cover these withholding obligations rather than requiring executives to arrange separate funding for tax payments.

This mechanism protects both the executive and the company by ensuring that tax obligations are met in a timely and orderly manner. By having the transaction occur at a predetermined price on the vesting settlement date, rather than requiring discretionary market sales, companies minimize potential complications related to insider trading windows, securities law compliance, and cash management. The disclosure of such transactions provides transparency to investors about executive equity holdings and transactions, even when those transactions are mandatory rather than elective.

Stock Price and Transaction Value Context

The shares were sold at $2.94 per share, generating gross proceeds of approximately $13,653 from the 4,644-share transaction before any transaction costs or fees. The immediate share price impact was not clear from available public information. The filing itself provides only the transaction price and does not include commentary on market conditions, trading volume, or the company's stock performance on or around July 23, 2026.

Investors analyzing the significance of this price should note that it represents the specific price at which the automatic tax withholding sale was executed. This price may or may not reflect open-market trading activity by other investors on that date. The restricted stock units that vested would have been valued at Opus Genetics' stock price on the settlement date, and that price determined both the executive's tax liability and the number of shares required to satisfy withholding obligations.

Disclosure Filing and Regulatory Requirements

The announcement was made through a Form 4 filing with the Securities and Exchange Commission, which is required for officers, directors, and ten-percent beneficial owners whenever their holdings of company securities change. Schachle, as Chief Operating Officer, is classified as an officer and therefore subject to Section 16 reporting obligations. The filing was signed on July 27, 2026, four days after the transaction execution, which is consistent with SEC rules requiring prompt disclosure of insider transactions.

The Form 4 document includes detailed tables showing the securities acquired or disposed of, the transaction code (in this case, "S" for sale), the amount and price of the transaction, and the beneficial ownership position following the transaction. The filing also includes an explanatory note clarifying that the sale was automatic and required to satisfy tax withholding obligations, providing context that distinguishes this transaction from discretionary stock sales by executives. This transparency is designed to help investors understand whether insider transactions reflect confidence or concern about the company's prospects, versus routine tax-driven mechanics.

Schachle's Role and Leadership at Opus Genetics

Joseph K. Schachle holds the position of Chief Operating Officer at Opus Genetics, Inc., a NASDAQ-listed company with its headquarters at 8 Davis Drive, Suite 220, in Durham, North Carolina. The filing confirms his officer status and his direct involvement in the company's operations. COOs typically oversee day-to-day business operations, supply chains, technology infrastructure, and other operational functions that support the company's core business activities.

The company did not disclose additional details about Schachle's tenure, responsibilities, or compensation package in this particular filing. Investors seeking broader context about Schachle's background, appointment date, or specific operational domains under his supervision would need to review proxy statements or other company disclosures that provide biographical and organizational information about senior management.

Tax Withholding Obligations and Equity Compensation Practices

Tax withholding obligations are a standard feature of restricted stock unit programs and other equity compensation arrangements. When an RSU vests, the recipient becomes subject to income tax on the value of the shares at vesting, typically calculated at the company's stock price on the settlement date. Federal, state, and sometimes local tax withholding is required before shares are delivered to the executive. Rather than requiring executives to pay withholding taxes from other funds, many companies offer or mandate an automatic "sell-to-cover" mechanism.

Under a sell-to-cover arrangement, the company automatically sells a sufficient number of shares at the vesting price to generate proceeds equal to the tax withholding obligation. This approach is efficient and minimizes the need for executives to arrange outside financing for tax payments. The filing's explanatory note confirms that Opus Genetics employed this standard practice, and that Schachle's share sale on July 23, 2026, was required by the company specifically to satisfy withholding obligations from the RSU vesting and settlement event.

Insider Transaction Transparency and Investor Monitoring

Form 4 disclosures provide investors with detailed transparency about insider transactions and holdings. By reviewing these filings, investors can track whether company executives are buying or selling shares, whether such transactions are discretionary or mandated, and the overall trend in insider ownership. Patterns of heavy insider selling might warrant investor attention as a potential signal of reduced confidence in the company's prospects, though mandatory tax withholding sales are not generally interpreted as such signals.

In Schachle's case, the automatic nature of the July 23 sale—explicitly stated in the filing's explanation—indicates that the transaction should not be read as a discretionary decision by the COO to reduce his equity stake. Instead, it represents a routine equity compensation administration activity. Schachle's retention of 291,440 shares following the sale demonstrates his continued significant direct ownership interest in Opus Genetics. Investors should monitor future Form 4 filings to identify any discretionary trading activity by Schachle or other executives that might reflect changing views about the company's value.

Power of Attorney and Filing Administration

The Form 4 was signed by Amy Rabourn on July 27, 2026, acting by power of attorney on behalf of Joseph K. Schachle. This indicates that Schachle authorized Rabourn to execute the regulatory filing on his behalf. Powers of attorney are common in corporate administration, allowing designated individuals to handle regulatory filings and related documentation without requiring the executive's personal signature on every document.

The use of a delegated signature authority does not change the substance or reliability of the disclosure. The filing remains the official record of the transaction and Schachle's beneficial ownership, and Schachle retains full responsibility for the accuracy and completeness of the information disclosed. The explanatory statements in the filing, including the clarification that the share sale was automatic and required, are part of the official record and binding on the reporting person.